Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New pim-1/2 inhibitors developed

Aug. 22, 2012

Investigation at Sphaera Pharma yields new PI3K/mTOR inhibitors

Aug. 22, 2012

Scientists at Novartis synthesize novel CDK9 inhibitors

Aug. 22, 2012

U.S. university and Novartis launch exclusive licensing agreement

Aug. 21, 2012

Investigational BCR-ABL inhibitor enters new phase I/II trial in Japan

Aug. 21, 2012

Proximagen discloses novel PAR2 receptor antagonists

Aug. 21, 2012

Dainippon Sumitomo Pharma establishes new oncology institute

Aug. 21, 2012

U.K. alliance set to launch AZD-8931 combination trial

Aug. 20, 2012

Lenvatinib obtains orphan drug status

Aug. 20, 2012

Enrollment complete in two Reolysin studies

Aug. 20, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...